Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.78 |
| ▸ | CSF1R | P07333 | 5/20 | 0.70 |
| ▸ | KIT | P10721 | 4/20 | 0.70 |
| ▸ | LCK | P06239 | 3/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 3/20 | 0.59 |
| ▸ | RAF1 | P04049 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | JAK3 | P52333 | 1/20 | 0.57 |
| ▸ | TEK | Q02763 | 1/20 | 0.57 |
| ▸ | BTK | Q06187 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5897754 | 0.85 | BRAF (1.00) | BRAFCSF1RKITLCKMAPK14 | |
| SCHEMBL14042456 | 0.84 | BRAF (0.69) | BRAFCSF1RKITLCKMAPK14 | |
| SCHEMBL14042433 | 0.83 | BRAF (0.68) | BRAFCSF1RKITLCKMAPK14 | |
| SCHEMBL14042158 | 0.83 | BRAF (0.68) | BRAFCSF1RKITLCKMAPK14 | |
| SCHEMBL14042145 | 0.82 | BRAF (0.73) | BRAFCSF1RKITLCKMAPK14 | |
| SCHEMBL14042437 | 0.82 | BRAF (0.67) | BRAFCSF1RKITLCKMAPK14 | |
| SCHEMBL7840189 | 0.82 | BRAF (0.93) | BRAFCSF1RKITKDRRAF1 | |
| SCHEMBL7840187 | 0.81 | BRAF (0.91) | BRAFCSF1RKITLCKMAPK14 | |
| SCHEMBL19073209 | 0.81 | BRAF (0.73) | BRAFCSF1RKITLCKMAPK14 | |
| SCHEMBL17992413 | 0.81 | BRAF (1.00) | BRAFCSF1RKITLCKMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | BRAF, NRAS, ARAF | BRAF 1/4885CSF1R 1740/4885KIT 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.